Mushrooms Archives - Green Market Report

Adam JacksonAugust 2, 2022
shutterstock_1959297163.jpg?fit=960%2C540&ssl=1

3min200

Red Light Holland Corp. (CSE: TRIP) (OTC Pink: TRUFF) posted its yearly audit results that show the company to be in healthy standing as it looks to expand its reach in the nascent market. The company filed its audited annual financial statements and management discussion & analysis for the financial year ending March 31, 2022.

The psychedelics maker audit results posted over $2.3 million in revenue and gross profit of over $600,000 — resulting in a gross margin percentage of 26.6% during a fiscal year in which they also oversaw four acquisitions. Not included was the recent acquisition of two retail stores in the Netherlands. The company also has working capital of around $26.1 million in cash. Property and equipment were valued at $2.9 million with total asset values at $32.9 million.

The company bore net losses of $14.7 million and $0.04 per share, which it said was significantly influenced by “non-cash charges relating to the impairment of intangible assets and goodwill in the amount of $5.9 million and stock-based compensation of $3.2 million.”

“As you know, I love marketing and brand building; we will push even harder in the near future with impactful marketing strategies with the continued goal of Red Light Holland being the leader in the Rec and Tech psychedelic sector,” CEO Todd Shapiro said. “We continue to identify and analyze near-term acquisition transactions while remaining cautious with our spending habits.”

“Our financial position and liquidity remain strong, and the company currently has sufficient capital to fund its ongoing business development and future growth and expansion plans for the foreseeable future,” CFO David Ascott said. “The working capital as of March 31, 2022, is $25 million which includes $26.1 million of cash and cash equivalents. During the year, we recorded a non-cash impairment loss against the intangible assets and goodwill in the amount of $5.9 million. Through our acquisitions, we added tangible capital assets including a mushroom production facility in New Brunswick valued at $2.5 million.”

 


Dave HodesJuly 12, 2022
mushroom-3.jpg?fit=667%2C1000&ssl=1

10min281

So much good news from trusted sources about psychedelics today has really made the topic part of the zeitgeist of a world looking for help, as we all struggle to deal with many mental health and wellness issues within the context of a worldwide pandemic showing new signs of continuing.

Psychedelics can adjust mood, enlighten thinking, and treat untreatable mental illness, according to most media reporting. Some psychedelics, like MDMA, also known as the club drug ecstasy, and “magic” mushrooms, have been powering the party scene for years

Now the word is that these psychedelics are more than just party drugs, and are being studied as good medicine, taking a long run through clinical trials. 

A party drug being used to treat depression sounds wrong to most people. But depending on how bad their depression is, most people with depression are willing to give it a try—right now. When suffering from depression or PTSD or any of the growing list of ailments that researchers are able to successfully treat with psychedelics, why wait for FDA approval that won’t happen until years of clinical trials are completed, which will finally allow a psychedelics-derived drug that your doctor can legally prescribe? 

If more and more highly qualified researchers and world-famous academic institutions are saying psychedelics are good for you, why wait for them to provide the kind of medical data that is needed to prove it as both effective and safe? It’s been a (relatively) safe party drug for years. What’s the holdup?

The reality is that it doesn’t take long to find psychedelics on the black market: LSD, MDMA, and psilocybin mushrooms are generally available from the same sources where you get your black market cannabis. Plus, psilocybin mushrooms can be easily grown at home with some home grow kits for under $100. 

“Magic” mushrooms are being discussed as a sort of cannabis-plus experience—easy to grow, fun to consume, a great party favor for all, safe, cool, available. Yet all that hype built on the desire to find another level of party buzz spells danger.

About 147 million people, or 2.5% of the world population, consume cannabis, a natural psychoactive plant. But psychedelics can powerfully alter perception, mood, and a host of cognitive processes in a much more profound way than cannabis does. Your first experience after ingesting a “magic” mushroom could be traumatic, even psychotic if you happen to have other psychological issues.

But hey, why not do a few grams of a psilocybin mushroom and experience that “magic” transformation? No worse than getting drunk, right?

One study concluded that a significant number of Americans are already “self-medicating” with psilocybin mushrooms. “As growing positive media coverage of psychedelics drives public interest in the health benefits of psilocybin mushrooms, this number will increase,” the study found.

Part of the perception about psilocybin as just another party substance is that a number of cities and states in the U.S. have decriminalized psychedelics (usually just psilocybin). But this wave of psychedelic decriminalization is not being accompanied by evidence-based regulation, according to the study.

Some industry observers believe that there’s a generational shift underway from recreational cannabis (legal in 19 states plus D.C.) to recreational psilocybin mushrooms (still illegal everywhere in the U.S.) as a sort of bonus buzz, popularizing them as never before.

And the marketing confusion instigated by both old and start-up mushroom product developers leads some to believe that psilocybin mushrooms are safe… good to dump in your morning coffee… OK to take before bedtime. 

But wait a minute: Those mushroom products crowding shelves in your local grocery stores are not psychoactive mushrooms, but instead just a marketing gimmick playing on what is reported to be the effects of psilocybin. 

You may be getting a buzz of some sort, but you are not tripping, even if the packaging and marketing still lead you to believe that is what is happening with these mushroom products.

Then there is the often misleading legalization of psilocybin. Recreational psilocybin (or adult use) as it’s being developed in Oregon and (probably soon) in Colorado, is not really recreational at all. It’s a medicine, used with therapy, in a controlled setting. 

Fun-looking packages of measured doses of psilocybin mushrooms will not be coming to the U.S. (though there are psilocybin truffle microdose products from The Netherlands) any time in the near future.

But right now, with all the talk about psilocybin, all the reports, the TV shows, and the celebrities talking about their experiences with psilocybin and other psychedelics, few people are following academic studies that reinforce the narrative that psilocybin, for instance, is a powerful mental health therapeutic. 

They just want to get a magical high, and get giggly, and get funny-spacey, like they see people on TV do. 

The dangers of taking “magic” mushrooms, not knowing how it will affect your mind, are real. This is not cannabis-plus. And ‘shrooming isn’t for everyone, no matter what anecdotal stories you hear. With any psychedelic, you are literally messing with important brain chemistry in a novel but very serious way. Choose your recreational buzz wisely.


StaffJuly 11, 2022
daily_hit001.png?fit=1200%2C344&ssl=1

8min210

The Daily Hit is a recap of the top cannabis business stories for July 11, 2022.

ON THE SITE

THC Designs Sued By Ex-Finance Director For Alleged Request To Doctor Financials

William McKenna, the former Finance Director for Los Angeles-based cannabis company THC Designs filed a lawsuit against the company on July 6, 2022. McKenna claims he was fired for refusing to defraud investors and tax authorities went the company’s owner Ryan Jennemann asked him to doctor the financials. He claims he was asked to reduce the liabilities so that the company could borrow more money. McKenna also thinks that the company was growing and selling psilocybin mushrooms for cash and not recording those sales. Read more here.

MediPharm Sells Australia Asset to OneLife Botanicals

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) is selling its MediPharm Labs Australia Pty Ltd to OneLife Botanicals PTY in a deal valued at $6.9M AUD ($6.2M CAD). The transaction is expected to close within 90 days. The deal includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from the Barrie GMP facility. Read more here.

Canadians Prefer To Pay Higher Prices For Flower

It seems Canadian cannabis consumers prefer to pay higher prices for flower. A new report from Cantor Fitzgerald’s analyst Pablo Zuanic found that most of the Canadian Licensed Producers (LP’s) increased market share with higher flower prices. The only exception to the rule was Organigram (NASDAQ: OGI), which saw its market jump dramatically after dropping prices almost by half. Read more here.

Neptune Wellness Revenue Drops As Company Leaves Cannabis

Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) announced its financial results for the fourth quarter and full-year ending March 31, 2022. The fiscal fourth-quarter revenue totaled $11.5 million, an increase of 147% versus $4.7 million for the same period the year prior. However, it was a big drop from the company’s fiscal third-quarter revenues of $18 million.  Neptune also trimmed its fourth-quarter net loss to $36.2 million versus a net loss of $43.5 million for the same quarter in 2021. Read more here.

New York Sends More Cease & Desist Letters

As the New York cannabis program moves at a snail’s pace to get the adult-use cannabis program established, numerous illicit operations have sprung up. With no real laws in place, technically most of these operators feel they can’t be charged with breaking the law. The law doesn’t exist. Plus, with cannabis mostly being decriminalized in the state, possession has also lost its threat. That has created a conflict between the legal medical cannabis operators who have spent millions creating companies that do comply with the law and the illicit operators. Plus, many are now investing even more money to try to become legal operators but watching the current illicit operators operate with impunity. Read more here.

New Lake Acquires More Properties

Cannabis REIT NewLake Capital Partners, Inc. (OTCQX: NLCP) reported $50 million of investments across three properties, marking the full commitment of capital raised during the company’s initial public offering (IPO). NewLake acquired two properties from a leading publicly-traded U.S. multi-state cannabis operator (MSO) and amended its existing lease with another leading publicly-traded U.S. MSO to fund an already completed expansion. As of June 30, 2022, NewLake has approximately $28.7 million of unfunded commitments. Read more here.

Psychedelics Market Grows Despite Many Unknowns

The psychedelics renaissance is in an expanded growth mode, not just in the U.S. and Canada, but in other countries as well. But everywhere in the world, it’s a bit of a Dr. Jekyll/Mr. Hyde scenario: startup businesses ostensibly building a serious moneymaking enterprise in a nascent industry, while conducting experiments in labs with novel brain-chemistry substances that could change the world of mental health wellness for good… if all goes as planned. Read more here.

IN OTHER NEWS

TILT Holdings Inc., Shinnecock Indian Nation

TILT Holdings Inc. (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development, and the Shinnecock Indian Nation, a federally recognized Native American tribe living on their traditional lands on the eastern end of Long Island, N.Y., began construction today on Little Beach Harvest, a 5,000 square-foot cannabis dispensary located on Shinnecock tribal territory in Southampton, N.Y. Read more here.

Flora Growth Corp.

Flora Growth Corp. (NASDAQ: FLGC), an all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today the appointment of Elshad Garayev to serve as Flora’s Chief Financial Officer, effective on the business day following the date on which the company files its mid-year financial results with the Securities and Exchange Commission. Until such time, Mr. Garayev will serve as Vice President of Finance and will work closely with Lee Leiderman, Flora’s current CFO, to ensure a smooth transition. Mr. Leiderman will then move into an advisory role with Flora in order to focus on his health and his family. Read more here.

Clever Leaves Holdings Inc.

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the continued expansion of the company’s partnership with European medical cannabis leader Cantourage GmbH to include supply of Clever Leaves’ second pharmaceutical-grade cannabis product, cultivated in the company’s Portugal Facilities, to the German medicinal cannabis market. Read more here.

Cannabotech

Cannabotech (CNTC.TA), an Israeli bio-med company which is engaged in the development of a botanical drug based on Cyathus striatus fungal extract and cannabinoids extracts from the cannabis plant, reports that further to an experiment in a cell model in April 2022, which proved that the fungus-cannabinoids combination kills pancreatic cancer cells with high efficacy of up to 100%. Read more here.


Dave HodesJune 27, 2022
mushroom-3.jpg?fit=667%2C1000&ssl=1

10min110

In Oregon, when voters approved Ballot Measure 109 calling for the legalization of psilocybin in November 2020, there was a silent hurrah throughout the state among people who took magic mushrooms for fun that went something like this: “Now we can go in to a psilocybin store and get a few grams of ‘shrooms—or maybe a handful—for the next concert.”

But that wasn’t the case. The measure was created to provide psilocybin for mental health therapy. It was strictly medicine. Wasn’t it?

Sometime early next year, if all goes according to plan, anyone over 21 will be able to go into a store in the state and buy magic mushrooms. But then they would have to sit through an “administration session” as a client of the facility, where they would consume and experience the effects of psilocybin under the supervision of a licensed psilocybin service facilitator. An “integration session” would follow where the client and a psilocybin service facilitator would discuss the experience.

It’s all pretty much just an extended doctor’s office visit, and brings into sharp focus what some believe to be the hollow victory of the state’s recreational psilocybin legalization: They are not for recreation at all.

Right now, the state is still in the process of setting up all the details of this psilocybin buying/selling/experiencing program. This includes: establishing rules by the end of the year; securing and customizing a product tracking system; creating an equity and justice centered approach to background checks; continuing to hire licensing and compliance teams; supporting the Oregon Psilocybin Advisory Board and subcommittees; creating education and training for their regulatory community and the public; and more.

But people looking for recreational fun with ‘shrooms don’t want to go to a medical clinic, or whatever these facilities will be morphing into as the regulations are developed and they begin operations. 

And outside of the concert or the dance club, people are beginning to use psilocybin as a smidgen of a bit of ‘shroom in their morning coffee, for example, to help set up a relaxing and productive day. That’s a trend that is catching on, rooted in Silicon Valley enterprises.

So the questions remain: Is legalized recreational psilocybin strictly medicine? Or can it also be a daily brain treat like some sort of advanced specialized brain health supplement? Or is it—will it become—a whole new recreational experience once people began tinkering with it outside of clinical studies and beyond the scope of any new regulations?

Not even the current Oregon state regulatory body can figure that out. Microdosing was not addressed, meaning that, even though recreational psilocybin is legal, microdosing is illegal right now. 

And there is confusion and debate around how medical Oregon’s psychedelics program will be structured. “I think there’s been a disconnect in what voters were told to expect when they voted and now. People will want mental health treatment but it’s not medical,” said Kimberley Golletz, a licensed psychologist and member of the Oregon Psilocybin Advisory Board giving guidance on the rules, as quoted in an article by Stat, a health and life sciences publication.

Real recreational legalization is part of the goal of Red Light Holland (OTC: TRUFF), an Ontario-based company that offers microdoses of magic truffles in their iMicrodose kit. A magic truffle is the fruiting body below the ground of the psilocybin mushroom. Magic truffles and magic mushrooms are both parts of the same organism that creates psilocybin, and have the same trippy effects after ingestion (though truffles’ effects are reportedly milder). Due to a loophole in Dutch law, magic truffles are legal but magic mushrooms are not. No therapists. No integration sessions. Just responsible adults going about their business buying magic truffles and enjoying their psilocybin experience.

Red Light Holland has been working on getting their products to other countries, such as Brazil and Canada, from their grow operations in The Netherlands. 

The company was created around the production, growth and sale of magic truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws. 

In an interview with The Street, an investment information company, Red Light Holland director and CEO Todd Shapiro said that he believes that magic truffles are a consumer goods product that is poised to cross more international borders. “We’re doing this because people are getting it anyway,” he said. “There are illicit markets anywhere you look. If people want to get access to this anyway, why not do it legally, why not do it carefully, and responsibly, and provide them that education that we are doing now. The careful use is the most important thing.”

So psilocybin is medical, but not… it’s illegal everywhere, except where it’s not… it’s turning into something like an uplifting food and beverage supplement to be combined with yoga or meditation, but that’s not really it either. It’s morphing, it’s evolving, it’s a moving target.

Perhaps the best thing that recreational psilocybin legalization has done is put more focus on achieving better brain health in general. According to results from an AARP survey, nearly one-quarter of adults age 18 and older currently take a supplement to maintain or improve brain health or delay or reverse dementia. That means that 58 million Americans (30 million age 50+) buy supplements believing it will help their brain health. Nine million adults age 50+ (8 percent) are taking a dietary supplement thinking it will actually reverse dementia.

Bottom line? There actually is no defined bottom line. But keep an eye on Oregon’s program, which could become the model of recreational psilocybin for other states as decriminalization continues—if all goes according to plan.


StaffNovember 2, 2021
mushroom.jpg?fit=960%2C640&ssl=1

3min271

Exclusively-natural psychedelic drug discovery company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH)  received authorization from the FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. The news caused the stock to jump over 11% in early trading.

The company said that this approval is the first for the direct administration of psilocin rather than its prodrug psilocybin and will administer Filament’s three proprietary botanical drug candidates. The phase 1 trial is led by the Translational Psychedelic Research Program (TrPR) at the University of California San Francisco (UCSF).

“We are excited to announce this milestone as validation of our ability to cultivate variable psychedelic biomass and transform it into pharmaceutical-grade drug candidates,” said Chief Executive Officer, Benjamin Lightburn. “Our innovative technology has allowed us to create IP-protected botanical drug candidates of oral psilocin, sublingual psilocin, and oral psilocybin, and to enter them into an FDA-approved natural psychedelic clinical trial. Our candidates enjoy significant IP protection, unlike most other psychedelics currently under clinical investigation.”

The phase 1 trial has been designed to include 20 healthy subjects and will examine the effects of Filament’s three proprietary botanical drug candidates: PEX010 (oral psilocybin), PEX020 (oral psilocin), and PEX030 (sublingual psilocin). As a result of the need for psilocybin to convert into psilocin before becoming active in the human body, the direct administration of psilocin may yield several therapeutic benefits such as faster onset time, greater consistency, increased bioavailability, and lessened side effects. These potential attributes are being studied in the authorized trial. In addition, psilocin is an ideal candidate for sublingual delivery because of the bypassing of the gut, where the conversion to psilocybin is thought to primarily occur. To date, synthetic manufacturers have been unable to produce a stable formulation of psilocin and enter it into a clinical trial.

“My team and I are very excited to begin dosing Filament’s drug candidates in our clinic,” said Dr. Josh Woolley, MD/Ph.D., Director of TrPR and the study’s Principal Investigator. “The oral and sublingual administration presents an opportunity to learn about psilocin’s effects compared to psilocybin and perhaps set a new standard for psychedelic assisted therapy.”


Debra BorchardtApril 29, 2020
shutterstock_1517440529-scaled.jpg?fit=960%2C640&ssl=1

7min210

Specialty life science company Revive Therapeutics Ltd. (CSE: RVV) has said that it will investigate novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on its wholly-owned patent-pending psilocybin formulations and its exclusive licensed drug delivery technology from the Wisconsin Alumni Research Foundation.

“We are expanding our psilocybin-based pharmaceutical portfolio with unique oral dosage and drug delivery forms that will target and have the potential to treat diseases and disorders currently not investigated with psychedelic compounds,” said Michael Frank, Revive’s, Chief Executive Officer. “We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies.”

The company said in a statement that through initial evaluations with its research team, it has found there are several unique parallels between the company’s intellectual property portfolio of psilocybin-based formulations and delivery mechanism and the drug delivery technology, which is comprised of tannin-chitosan composites that have been studied with cannabidiol in the past.  Revive said it intends to research both delivery mechanisms in parallel as each provides its own unique qualities such as the potential of rapid onset of action and time-release compositions.

New Interest in Psilocybin

Psilocybin is being viewed as a treatment for several conditions including drug-resistant depression. Studies have been performed to illustrate the efficacy of psilocybin for this specific purpose. One completed study found that psilocybin produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. The study was published in 2016, and wrote that “At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction.”

According to the World Health Organization, almost 350 million people worldwide were affected by depression in 2016. Common antidepressant drugs help maintain the balance of various hormones and chemicals in the brain, which assists in the treatment of depression.

The Center for Disease Control and Prevention (CDC), reported that the percentage of people above the age of 12 years using antidepressants in the U.S. rose to 12.7% in 2011-2014. According to MedGadget, the antidepressant drug market was valued at $13.69 billion in 2018 and is expected to reach $15.88 billion by 2025. The CDC said that in the U.S., antidepressants were the most commonly prescribed drugs in 2013 and from over 16 million long term users, around 70% are female.

Psilocin Acquisition

In March, Revive completed its acquisition of Psilocin Pharma Corp., a specialty psychedelic sciences company focused on the development of Psilocybin-based therapeutics for significant unmet medical needs including rare and orphan indications. Psilocin developed patent-pending formulation and production solutions for the active compound Psilocybin.  The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations.

In a statement, the company noted that Psilocin has also developed formulations to date which include the Hydroxy Line.  The line will include PSY-0.1 -Capsules- PSY-0.2 -Sublingual Spray- PSY-0.3 -Gel Cap- PSY-0.4/0.5 -Effervescent Tablets-and PSY-0.6 -Breath Strips.  The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration (“FDA”) approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases.  Psilocin’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption

Best Delivery Method

Revive believes that the most optimal delivery method to deliver psilocybin will be in the form of both an oral dissolvable tablet and an oral thin film strip, commonly recognized as a ‘Breath Strip’.  The company said that it is preparing its formulation development plans to pursue clinical studies for indications currently not being evaluated with psilocybin.

The company reported that it has key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of psilocybin-based formulations, including sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (i.e. gum drops, oral strips, dosing pens). In addition to those patent applications, Revive has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies.

The delivery technology is a natural, non-toxic, biodegradable, and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.

Revive is also exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.


StaffApril 22, 2020
mushroom.jpg?fit=960%2C640&ssl=1

5min100

The Campaign to Decriminalize Nature DC (DNDC) released the results of a new poll on April 21 that showed support for mushroom decriminalization in Washington DC. The “Initiative 81, the “Entheogenic Plant and Fungus Policy Act of 2020,” has enough support to pass in the District of Columbia according to a survey completed by Fairbank, Maslin, Maullin, Metz & Associates (FM3).

The poll sponsored by the New Approach PAC demonstrated that a majority of DC voters support Initiative 81, a measure that would make enforcement of existing restrictions on plant medicines or entheogens among the Metropolitan Police Department’s lowest law enforcement priorities. Of those polled, 51% support the initiative based on the text of the measure alone. When presented with a plain-language explanation, that support grows to 60% and continues to increase and solidify as voters learn more.

Here’s the initial language that didn’t have as positive of a response:

ENTHEOGENIC PLANT AND FUNGUS POLICY ACT OF 2020. If enacted, this Initiative would: Make the investigation and arrest of adults for non-commercial planting, cultivating, purchasing, transporting, distributing, possessing, and/or engaging in practices with entheogenic plants and fungi among the Metropolitan Police Department’s lowest law enforcement priorities; and codify that the people of the District of Columbia call upon the Attorney General for the District of Columbia and the United States Attorney for the District of Columbia to cease prosecution of residents of the District of Columbia for these activities

Here’s the easier to understand language:

It would change current law having to do with plant medicines known as entheogens, which include substances
like psilocybin, the active ingredient in “magic mushrooms”; cacti which contain mescaline, iboga, which contains
ibogaine and ayahuasca, which contains DMT. The measure would make investigation and arrest of adults for
non-commercial growing, gathering, and gifting of these plant medicines among the lowest law enforcement
priorities for the District of Columbia. The measure instructs the DC Attorney General to not prosecute people
arrested for entheogens. The measure does not legalize these substances, allow their retail sales, or permit
marketing of any products containing these substances

One issue that was identified was the lack of knowledge about the products. The survey determined that fewer than one-quarter have a close tie to someone who has used psilocybin; very few have personally used ayahuasca, mescaline or iboga, or know someone who has. Having said that, many DC voters have a connection to
someone who has experienced the type of mental health issues the substances can treat.

Among the more than 800 likely DC voters reached by phone as part of this poll, prioritizing law enforcement’s role in reducing violent crime and protecting personal freedom were consistently cited as top reasons for supporting Initiative 81.

These results come as the DNDC faces unprecedented challenges due to the COVID-19 coronavirus pandemic. Necessary social-distancing measures, including DC Mayor Murial Bowser’s stay-at-home order, have made traditional in-person petitioning and signature collection impossible. To preserve ballot access during this public health emergency, DNDC has requested that the DC Board of Elections and DC Council find alternatives to the in-person petition process. Time is running out for DNDC to qualify for the November ballot with 30,000 signatures needed by Monday, July 6th.

“This poll demonstrates the broad support for Initiative 81 in the District of Columbia and reaffirms the importance of putting the “Entheogenic Plant and Fungus Policy Act of 2020,” on the November ballot,” said Melissa Lavasani, the proposer of Initiative 81. “Despite the current public health crisis, DC voters have made clear that they are ready to change how DC approaches entheogens. Now our campaign must make sure that voters have the opportunity to do so.”


Debra BorchardtApril 7, 2020
mushroom.jpg?fit=960%2C640&ssl=1

4min110

NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) has signed a letter of intent to purchase Colorado-based  Mydecine Group in an all-stock deal valued at $850,000.  Mydecine is a vertically integrated company engaged to utilize the vast medicinal, health and wellness capabilities of the many compounds found in various strains of mushroom and fungi as a whole.

“We’ve been watching and closely monitoring the progress of the mycology space for some time now. Given that we are located in the home state to first decriminalize psilocybin in the U.S., the Company has had a unique opportunity to get a jump on the potential industry as a whole,” said Joshua Bartch CEO of NewLeaf Brands in a statement. “So far, Denver and Oakland have decriminalized psilocybin, while Oregon has a measure to legalize the substance as soon as this year! We share a common vision of Mydecine in the sense of seeing the vast potential of mycology as a whole, not just the compound psilocybin. Numerous other compounds found in fully legal fungi are very exciting and hold the potential to make truly revolutionary discoveries, IP and products.  We see this as an incredibly early opportunity with enormous potential upside.”

Mydecine has three wholly-owned divisions, “Mydecine Farms”, “Mydecine Wellness”, and “Psydecine Labs.” The company aims to be an industry pioneer in the cultivation, processing, product development, and research and development of the many beneficial and exciting compounds that are found in various strains of mushroom and fungi from all around the world.

The company noted in a statement that numerous compounds found in various strains of mushroom and fungi are already being used to develop treatments for health conditions such as depression, PTSD and opiate addiction. Meanwhile, in 2019, the National Alliance on Mental Illness had stated that 1 in 6 youths aged 6-17 in the U.S. experience a mental health disorder each year and 1 in 25 U.S. adults experience a serious mental illness each year.

NewLeaf Brands is a CBD lifestyle Company. It owns the subsidiaries We are Kured, LLC, Drink Fresh Water, LLC, ReLyfe Brand, LLC and TeaLief Brand, LLC. The company’s main business activities encompass the development, marketing, and distribution of CBD products (including vaporizer pens/cartridges, hot/cold tea, softgel capsules and beverages) throughout North AmericaSouth America, and Europe. In addition, NewLeaf Brands, Inc. has extensive retail and cultivation land investments in Oregon, USA.

The NewLeaf stock trades at seven cents per share and the company has a market cap of roughly $2 million.

 

 


Noemi GonzalesApril 3, 2020
792399-v0_5-GMR-BC-FB.png?fit=960%2C469&ssl=1

6min81

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, Cultivate and use Cannabis and Psychedelic Mushrooms even for Medical Use. A High Trip to the Knowledge You Will Not Forget!” by Tommy Smith – Review

 Now here’s a dynamic duo of topics to discuss: cannabis and mushrooms.

Author Tommy Smith has put together a very solid compilation of data focused on helping the reader better understand the risks, how to cultivate, various uses, and other useful information when it comes to both cannabis and magic mushrooms. There is still much inaccurate information prevalent on these topics so the more genuine content we see circulating then all the better.

This book will teach you how to create an ideal environment to grow mushrooms in your home, decide whether or not to grow indoors or out, how to begin growing marijuana, how to identify various types of mushrooms and so much more.

Did you know that around 5,000 BC that the Chinese were among the first cultures to regularly cultivate and consume cannabis?

See? You’re learning already!

-Topic Focus-

So much good content packed into this book about both cannabis and mushrooms. Where to begin?

You will find this book useful if you:

  • Want to learn how to begin growing cannabis
  • Want to learn how to begin growing mushrooms
  • Want to learn about the medicinal benefits of both cannabis and mushrooms
  • Are interested in the history surrounding cannabis and mushrooms

About the Author

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, cultivate and use cannabis and Psychedelic Mushrooms even for medical use. A high trip to the knowledge you will not forget!” author Tommy Smith quickly displays both expertise on these topics and a passion for them as you read this book.

You can tell that Tommy truly cares about sharing this information in the way that the book is written as well as the fact that so much useful content is shared for such a low price. Very generous.

-Reading Experience-

This book gets right to work with no fluff or hyperbole and dives right into the history and starts from the ground up with an introduction to what cannabis is, what THC is, and a brief history of it’s legalization status over the years. It felt like author Tommy Smith just couldn’t wait to start sharing his expertise with the reader.

There are many of us who struggle to learn tasks such as cultivation so having a guide that is simple to follow is an incredibly useful tool. The information presented is done so in a way that is easy to interpret and take action from.

Not only are the medicinal benefits of cannabis and mushroom use discussed here, but so are the potential risks that accompany such use. Many people involved in these industries tend to display consumption in a positive light without discussing potential risks so being willing to address the potential negatives of such consumption lends the writer a degree of credibility.

-Summary-

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, cultivate and use cannabis and Psychedelic Mushrooms even for medical use. A high trip to the knowledge you will not forget!” by Tommy Smith is over 300 pages that get right to work teaching you useful content and is only $6.90 (at the time of writing) so you can’t really go wrong grabbing your copy.

The content is clearly written in a way that communicates how familiar the author is with these topics while also making cultivation feel all the more accessible. If you are not already an expert on cannabis then there is definitely much here for you to dive into. Even the more veteran among us can learn a thing or three from this useful book.

If you are ready to begin your own educational journey regarding cannabis and mushrooms then get your copy here: https://www.amazon.com/Magic-Mushrooms-Marijuana-Understand-Psychedelic

 


StaffJanuary 21, 2020
shutterstock_1526869721-scaled.jpg?fit=720%2C960&ssl=1

3min140

Just as the psilocybin mushroom market begins to heat up, one enterprising entrepreneur has quickly snapped up the trademark for the word “Psilocybin.” Marijuana Moment picked up on the founder’s notice on LinkedIn that the word had been trademarked. That post has since disappeared and while there is no mention of the trademark happening on the company’s website, the tiny TM does appear after each mention of the word Psilocybin on the company’s website.

The company sells chocolate bars, that don’t seem to contain any mushroom ingredients. In fact, there is little in the way of a description as to how the chocolate is made or sourced. It says the bars “have been created as a gateway to educate you on what is next for medicinal mushroom health and healing.” It does say that all the products are sold out.

Scarlet Ravin describes her company Psilocybin™️ as “a community-based support system holding a sacred knowing for others to come back to their knowing of their God-self.” She describes herself as being “known for her visionary Branding and Marketing which has led her companies to the front of the market allowing multiple press mentions and forward-thinking concepts that grab the attention of the mass market.”

Ravin told Marijuana Moment that she “plans to contribute 10 percent of profits to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is involved in researching the therapeutic benefits of psychedelic substances.”

Marijuana Trademarks Not Allowed

Psilocybin mushrooms are also a schedule 1 substance under the Controlled Substance Act like marijuana. The U.S. Patent Trade Office stated that marijuana is still prohibited from U.S. trademark registration. “The CSA prohibits, among other things, manufacturing, distributing, dispensing, or possessing certain controlled substances, including marijuana. 21 U.S.C. §§812, 841(a)(1), 844(a). Therefore, the USPTO refuses registration when an application identifies goods encompassing CBD or other extracts of marijuana because such goods are unlawful under federal law and do not support valid use of the applied-for mark in commerce.”

Marijuana Moment noted that this trademark is “Specifically for educational materials and it’s listed on the supplemental register, rather than the principal register, which means it would be incumbent upon the brand to prove that it has earned distinctiveness of the mark if the issue went to court.”

 

 

 


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 days

Researchers Seek to Remove ‘Trip’ as Popularity of Psychedelic Treatments Grows

@GreenMarketRpt – 3 days

The Weekly Stash Video September 30, 2022

@GreenMarketRpt – 3 days

Florida Drops Criminal Charges Against Former Ascend Wellness Chief

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.